Literature DB >> 3946465

Chronic congestive heart failure. Where have we been? Where are we heading?

M M Applefeld.   

Abstract

Chronic congestive heart failure is a frequently occurring disease associated with an impaired quality of life and significant mortality rate. Progress has been made in dissecting the pathophysiologic changes of congestive failure and in using vasodilators, newer positive inotropic agents, and other treatment modalities. Despite these advances, the overall mortality rate from congestive heart failure has not decreased. Further, many unanswered questions remain: How and why does a myocardial cell die? How should quality of life be measured? When should vasodilators and positive inotropic agents be given? What role do receptors play in pathogenesis and therapy? Can sudden death in heart failure be prevented? These and other questions will provide the stimulus for further studies in congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3946465     DOI: 10.1016/0002-9343(86)90149-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Costs associated with symptomatic systolic heart failure.

Authors:  P G Davey; P B Clarkson; A McMahon; T M MacDonald
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

Review 2.  Clinical and economic factors in the treatment of congestive heart failure.

Authors:  R Andrews; A J Cowley
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

3.  Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine.

Authors:  P M Schofield; N H Brooks; G P Lawrence; H J Testa; C Ward
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

4.  Determining the effectiveness of torasemide and furosemide in heart failure: design of a randomised comparison using the regenstrief medical record system.

Authors:  M D Murray; W M Tierney; D C Brater
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.